What do systematic reviews say?

Summary of findings: fat‐soluble vitamin E vs control

The review found no eligible studies for this question.

• Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: fat‐soluble vitamin E vs control

The review found no eligible studies for this question.

• Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: fat‐soluble vitamin E vs control

• Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  6 participants
  GRADE not reported

Vitamin D plus calcium vs placebo or control

Vitamin D [D2, D3 or 25(OH)D] plus calcium showed no clear difference in persons with hypercalcaemia ‐ Vitamin D (D2, D3 or 25(OH)D) plus… compared with control or placebo (low certainty).

• Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men 2014 · Cochrane Headline outcomes only
  RR 3.29 [0.37, 29.14]
  2 studies · 3853 participants
  Low

Vitamin D plus calcium vs placebo or control

Vitamin D [D2, D3 or 25(OH)D] plus calcium leads to higher persons with renal disease (calculi or insufficiency) ‐ Vitamin D… compared with control or placebo (high certainty).

• Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men 2014 · Cochrane Headline outcomes only
  RR 1.17 [1.03, 1.34]
  2 studies · 39552 participants
  High

Vitamin D plus calcium vs placebo or control

Vitamin D [D2, D3 or 25(OH)D] plus calcium showed no clear difference in deaths ‐ Vitamin D (D2, D3, 25(OH)D) plus calcium (1 year estimate) compared with control or placebo (high certainty).

• Vitamin D and vitamin D analogues for preventing fractures in post‐menopausal women and older men 2014 · Cochrane Headline outcomes only
  RR 0.94 [0.87, 1.02]
  6 studies · 46794 participants
  High

Summary of findings: water‐soluble vitamin E vs control

The review found no eligible studies for this question.

• Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: water‐soluble vitamin E vs control

Summary of findings: water‐soluble vitamin E may leads to higher vitamin E levels in serum: umol/L compared with control (low certainty).

• Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  MD 19.74 [13.48, 26]
  1 study · 45 participants
  Low

Summary of findings: water‐soluble vitamin E vs control

The review found no eligible studies for this question.

• Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: water‐soluble vitamin E vs control

The review found no eligible studies for this question.

• Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin E vs placebo

It is very uncertain whether vitamin E changes progression to late AMD (neovascular AMD, geographic atrophy or both) compared with placebo (very low certainty).

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  RR 1.36 [0.31, 6.05]
  1 study · 998 participants
  Very low

Vitamin E vs placebo

The review found no eligible studies for this question.

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin E vs placebo

The review found no eligible studies for this question.

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin E vs placebo

Vitamin E showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  RR 1.04 [0.74, 1.47]
  1 study · 1179 participants
  Low

Vitamin E vs placebo

The review found no eligible studies for this question.

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin E vs placebo

It is very uncertain whether vitamin E changes adverse effects compared with placebo (very low certainty).

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  4 participants
  Very low

Vitamin E vs placebo

The review found no eligible studies for this question.

• Antioxidant vitamin and mineral supplements for slowing the progression of age‐related macular degeneration 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Vitamin D vs placebo

• Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1188 participants
  Moderate

Vitamin D vs placebo

• Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1023 participants
  Very low

Vitamin D vs placebo

Vitamin D showed no clear difference in mortality rate ( compared with placebo (low certainty).

• Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia 2023 · Cochrane Headline outcomes only
  RR 0.69 [0.44, 1.07]
  3 studies · 584 participants
  Low